Velpatasvir, an antiviral agent co-formulated with sofosbuvir used to treat hepatitis C, has recently demonstrated beneficial therapeutic effects against COVID-19. Therefore, therapeutic drug monitoring of velpatasvir is essential to achieve the desired clinical outcomes. An electrochemical sensor modified with synthesized copper oxide nanoparticles on the surface of graphene oxide (CuO/GO-NPs) was fabricated for the analysis of velpatasvir for the first time. Characterization was carried out using Fourier-transform infrared spectroscopy, X-ray diffraction, and scanning electron microscopy with energy-dispersive X-ray spectroscopy. The voltammetric determinations were conducted using differential pulse and cyclic voltammetry, where the modified electrode exhibited better sensitivity than the unmodified one. The method was validated according to the International Council for Harmonisation (ICH) guidelines, exhibiting linearity within a range of 1.0 ×10-7 – 1.0 × 10-5 M, covering velpatasvir’s maximum plasma concentration (Cmax), with a quantification limit of 2.89 × 10-7 M and a detection limit of 9.03 × 10-8 M. The developed sensor was successfully applied to spiked human plasma at velpatasvir’s Cmax level. The method’s greenness was assessed using the Analytical Eco-scale and the Green analytical procedure index tools. This method holds promise as a green simple approach to implemented in future velpatasvir’s therapeutic drug monitoring studies.